Adipose tissue-derived stem cells from affected and unaffected areas in patients with multiple symmetric lipomatosis show differential regulation of mTOR pathway genes

Issue title: Special Issue in Honour of the Editor-in-Chief Prof. Dr. Ing. Friedrich Jung on his 70th Birthday

Article type: Research Article

Authors: Felthaus, Oliver^{a; *} | Schön, Teresa^a | Schiltz, Daniel^a | Aung, Thiha^a | Kühlmann, Britta^a | Jung, Friedrich^b | Anker, Alexandra^a | Klein, Silvan^a | Prantl, Lukas^a

Affiliations: [a] Department of Plastic-, Hand-, and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany | [b] Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies, Helmholtz-Zentrum Geesthacht, Kantstrasse, Teltow, Germany

Correspondence: [*] Corresponding author: Dr. Oliver Felthaus, Center of Plastic -, Hand-, and Reconstructive Surgery, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. E-mail: oliver.felthaus@ukr.de.

Abstract: BACKGROUND:Multiple symmetric lipomatosis is a rare disease characterized by the excessive growth of uncapsulated masses of adipose tissue. Although the etiology has yet to be elucidated, a connection to brown adipose tissue has been proposed recently. The mTOR pathway which is found to be regulated in lipomatous tissue as well as associated with brown adipose tissue can be inhibited by a compound called rapamycin. METHODS:We isolated adipose tissue derived stem cells from both affected and unaffected tissue and treated these cells with different concentrations of rapamycin. RESULTS:The differences in both proliferation and differentiation between adipose tissue derived stem cells (ASCs) from lipomatous and normal tissue decreased after mTOR pathway inhibition. In some patients regulation of mTOR genes was opposed in the ASCs from the two different tissues. CONCLUSIONS:Treatment with rapamycin might be a novel therapeutical approach for patients suffering from multiple symmetric lipomatosis.

Keywords: Multiple symmetric lipomatosis, rare disease, mTOR pathway, rapamycin

DOI: 10.3233/CH-189107

Journal: Clinical Hemorheology and Microcirculation, vol. 69, no. 1-2, pp. 141-151, 2018